Physician profile
David Levi Nathan
NPI 1619963998
$4,270.45
in general payments reported to CMS, 2019-2025
22 companies · $722 in 2025
The $722 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $667 · 2020: $568 · 2021: $845 · 2022: $525 · 2023: $471 · 2024: $473 · 2025: $722.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,644 · Education: $22.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,644.30 |
| Education | $22.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,245.39 | 2019-2025 | |
| Janssen Biotech, INC. | $650.66 | 2019-2025 | Tremfya |
| Pfizer INC. | $635.10 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $392.76 | 2021-2025 | Dupixent, Libtayo |
| Amgen INC. | $266.59 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $157.76 | 2022-2024 | Sotyktu |
| Galderma Laboratories, L.P. | $135.88 | 2021-2025 | Nemluvio |
| Novartis Pharmaceuticals Corporation | $113.45 | 2024-2025 | |
| Sun Pharmaceutical Industries INC. | $108.03 | 2020-2024 | |
| Janssen Scientific Affairs, LLC | $91.10 | 2019-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $85.51 | 2019-2021 | |
| Ucb, INC. | $83.34 | 2021-2025 | Bimzelx |
| Leo Pharma INC. | $66.88 | 2022-2025 | Anzupgo |
| Incyte Corporation | $61.65 | 2022-2024 | Opzelura |
| Verrica Pharmaceuticals INC. | $42.73 | 2023-2025 | Ycanth |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cipher Pharmaceuticals US LLC | $26.90 | 2025 | Natroba, Spinosad |
| Convatec INC. | $25.26 | 2024 | |
| Dermavant Sciences, INC. | $22.59 | 2023 | Vtama |
| Astrazeneca Pharmaceuticals LP | $17.05 | 2023 | |
| Genentech USA, INC. | $15.91 | 2023 | Xolair |
| Lnhc, INC | $14.40 | 2025 | Zelsuvmi |
| Organon LLC | $11.51 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Nathan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.